CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Make some room on ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

Duloxetine is an antidepressant, with a specific batch having been recalled due to the presence of potentially cancer-causing impurities.

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Findings show persistent posttreatment genital hypoesthesia among sexual and gender minority youth with history of ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...